No Data
Analysis of Zhitong Hong Kong Stock Connect Holdings | April 3rd
Analysis of Hong Kong Stock Connect Holdings | April 2, 2025
Analysis of Zhito Hong Kong Stock Connect Holdings | April 2
Hong Kong Stock Connect Holdings Analysis | April 1, 2025
BAIYUNSHAN PH (00874.HK) subsidiary's pharmaceutical has passed the consistency evaluation of generic drugs.
Gelonghui, March 28 | BAIYUNSHAN PH (00874.HK) announced that recently, its holding subsidiary Guangzhou BAIYUNSHAN TIANXIN Pharmaceutical Co., Ltd. received the "Notice of Approval for Pharmaceutical Supplementary Application" issued by the National Medical Products Administration, indicating that injectable ampicillin sodium (1.0g, 0.5g) has passed the consistency evaluation of generic drug quality and efficacy. Tianxin Pharmaceutical's injectable ampicillin sodium (1.0g, 0.5g) was launched in 2002. In 2023, Tianxin Pharmaceutical submitted the consistency evaluation for injectable ampicillin sodium (1.0g, 0.5g) to the National Medical Products Administration on November 28.
BAIYUNSHAN PH (00874.HK): Hepatitis B detox capsules and others have received approval for supplementary applications.
On March 28, Glonhui reported that BAIYUNSHAN PH (00874.HK) announced that its subsidiary, Guangzhou BAIYUNSHAN PH Pharmaceutical Group Co., Ltd. BAIYUNSHAN PH Pharmaceutical Factory (hereinafter referred to as "BAIYUNSHAN PH Pharmaceutical Factory"), received the "Pharmaceutical Supplement Application Approval Notice" issued by the National Medical Products Administration. This time, BAIYUNSHAN PH Pharmaceutical Factory has obtained the "Pharmaceutical Supplement Application Approval Notice" for Hepatitis B detoxification capsules and Rhododendron capsules, which improves the safety information and other details of the above pharmaceuticals, aiding in their safe, effective, and rational use, and enhancing the market competitiveness of the product. This time, the "Pharmaceutical Supplement Application Approval Notice" has been obtained.
BAIYUNSHAN PH (600332.SH): Injection of sodium ampicillin has passed the consistency evaluation for generic drugs.
On March 28, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its holding subsidiary, Guangzhou BAIYUNSHAN PH Tianxin Pharmaceutical Co., Ltd., received the "Pharmaceutical Supplement Application Approval Notice" issued by the National Medical Products Administration, indicating that the injectable Ampicillin Sodium (1.0g, 0.5g) has passed the consistency evaluation of quality and efficacy for generic drugs. Injectable Ampicillin Sodium is a broad-spectrum semi-synthetic penicillin used for respiratory infections, gastrointestinal infections, urinary tract infections, soft tissue infections, endocarditis, meningitis, sepsis, and other infections caused by sensitive bacteria.
Baiyunshan Pharma's Subsidiary Gets Nod to Trial Yupingfeng Tea Bag as Treatment For Hypothyroidism
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down